Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

What Was Tested

Researchers studied Cagrilintide and Semaglutide in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, the researchers enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication.

Effect estimates were assessed with the treatment-policy estimand (consistent with the intention-to-treat principle).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Cagrilintide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Cagrilintide.

Some participants received a placebo instead of Cagrilintide, giving a reference point.

More than one site took part, so the participants came from several places.

What Was Measured

PubMed files the paper under topics including Anti-Obesity Agents, Body Mass Index, Obesity, Overweight, Weight Loss, Islet Amyloid Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and Semaglutide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (The New England journal of medicine), a journal based in United States.

More context: the Cagrilintide compound page and the Semaglutide compound page, all human trials.